Regonix 2017-07-25T05:18:27+00:00

Regonix

Regorafenib 40 mg

Regorafenib is an oral tumor deactivation agent that inhibits multiple kinases and signaling cascades.

Regonix

Inhibition of proliferation

Inhibition of stromal signaling

Inhibition of neoangiogenesis

Indication :

Colorectal Cancer

Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with Fluoropyrimidine-, Oxaliplatin- and Irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wildtype, an anti-EGFR therapy.

Gastrointestinal Stromal Tumors

Regorafenib is indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with Imatinibmesylateand Sunitinib malate.

Hepatocellular Carcinoma

Regorafenib is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Sorafenib

Finding the cure starts with hopE

Continues Life with Regoranib